Explore our library of Olink application-related articles! Use the drop-down menu below to filter on specific categories of content.
Ensuring quality with flexibility- Olink® Flex validation & verification
This white paper transparently presents some of the results from our verification and validation tests carried out during the development of Olink Flex.
Inflammatory protein biomarkers of human diseases
The study of cytokines, chemokines, their respective receptors and many other types of proteins involved in inflammatory and immune response processes has been pivotal in our understanding and treatment of human disease. Olink® panels focused on inflammation-related proteins have been used extensively in such studies.
It’s all relative – 4 reasons why biomarker discovery commonly uses relative quantification
In this white paper, four reasons why relative quantification remains the prevalent method for biomarker discovery are provided.
Repurpose drugs for new indications
New applications through deeper understanding of disease patho-mechanisms
Protein biomarkers to predict drug response
Successful application of drugs to the right patients
Pathophysiological insights to better understand drug mode of action
Match disease endotypes to your drug’s mode of action
Stratification of patients for more effective, cost-efficient clinical trials
Reduce the size and cost of clinical trials by identifying likely responders during selection of enrolees
Identify non-invasive biomarkers
Save time/cost/inconvenience of invasive sampling (tissue biopsies, imaging etc)
Robust drug target selection
Identify protein biomarkers that are causal for diseases
Proteomics in drug development
Incomplete knowledge of the real-time biology underlying disease and drug action can drive up costs and time in drug development. Protein biomarkers, along with other omics markers, can be used to predict response, stratify patient populations, and provide insights into the biology of disease.